Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (DE:F6T)
FRANKFURT:F6T
F6T Stock Chart & Stats
€0.98
€0.07(3.83%)
At close: 4:00 PM EST
€0.98
€0.07(3.83%)
Day’s Range― - ―
52-Week Range€0.60 - €1.49
Previous CloseN/A
Volume185.00
Average Volume (3M)120.00
Market Cap
€113.92M
Enterprise Value€162.60M
Total Cash (Recent Filing)€203.66M
Total Debt (Recent Filing)€77.85M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
May 06, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding116,263,460
10 Day Avg. Volume0
30 Day Avg. Volume120
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.96Price Target Upside99.78% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.96
Revenue Forecast (FY)€5.01M
Bulls Say, Bears Say
Bulls Say
Administration ScalabilitySuccessful outpatient administration of the cell therapy without intensive conditioning could remove logistical barriers and enhance the potential for broader clinical adoption and scalable delivery.
Clinical Development MomentumProgression of the engineered FT819 cell therapy with expanding enrollment and added international trial sites signals development momentum that could support advancement toward pivotal studies across autoimmune indications.
Regulatory SupportRegulatory fast-track designation and a defined path for a pivotal trial in systemic lupus erythematosus and lupus-related kidney disease could streamline review and improve clarity on approval expectations.
Bears Say
Limited Clinical DatasetTreatment of only a small number of patients restricts confidence in safety and efficacy findings, creating uncertainty until larger clinical datasets are available.
Fate Therapeutics News
F6T FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was €0.60 and its highest was €1.49 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is €113.92M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is May 06, 2026 which is in 49 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Feb 26, 2026. The company reported -€0.235 earnings per share for the quarter, the consensus estimate of -€0.235 by €0.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 116,263,460 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -€0.235 in its last earnings report, expectations of -€0.235. Following the earnings report the stock price went down -9.125%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in DE:F6T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.96 (99.78% Upside)
€1.96 (99.78% Upside)
Blogger Sentiment
Bullish
DE:F6T Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $16.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.27%
12-Months-Change
Fundamentals
Return on Equity
-55.02%
Trailing 12-Months
Asset Growth
-27.63%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
F6T Stock 12 Month Forecast
Average Price Target
€1.96
▲(99.78% Upside)
Technical Analysis
Options Prices
Currently, No data available
---